Dongnam Chemical: Profit Recovery in H1 2026 Alongside Buybacks and a Wide Model Range

Thesis

The data supports a picture of improving profitability. Trailing operating margin is 6.7% against 4.8% in each of 2023 to 2025, and trailing ROE is 19.6% against 12.9% in 2025. Trailing P/E of 9.5 is below the year-end P/E of 16.5 to 20.0 seen in 2021 to 2025. Treasury stock purchases and a cash dividend decision in July 2026 point to shareholder returns, with a dividend yield of 3.1%.

The data does not show why margins improved or whether that will last. Revenue has been uneven (-13.8% in 2023, then +11.8% and +4.2%). The share price fell 5.9% over one month and 5.5% over one year, so the market has not fully followed the earnings rise. No news headlines are available, so the data cannot explain recent moves.

Business overview

Dongnam Chemical Co., Ltd. was founded in 1965 and listed on KOSPI in 1996. It operates in the Chemicals sector and is led by co-CEOs Kim Jung-don and Park Mi-ryung. Market capitalisation is ₩105.4B across 3.5M listed shares, making it very small next to the peers listed (LG Chem at ₩16.8T, for example). Foreign ownership is 0.2%, unchanged from 60 days ago, and the short balance is 0.2%. The data does not describe its products or customers.

Financial analysis

These figures come from filed financial statements. Revenue was ₩160.3B in 2021, ₩193.4B in 2022, ₩166.7B in 2023, ₩186.4B in 2024 and ₩194.3B in 2025. Trailing revenue to H1 2026 is ₩216.6B.

Operating income fell from ₩14.9B in 2021 to ₩8.1B in 2023, then reached ₩9.4B in 2025 and ₩14.6B on a trailing basis. Net income followed the same path: ₩11.7B in 2021, ₩6.0B in 2023, ₩7.0B in 2025 and ₩11.0B trailing. Operating margin was 9.3% in 2021 and 4.8% in 2025, and is 6.7% trailing. Net margin is 5.1%.

The balance sheet shows liabilities to equity of 96.7%, cash of ₩8.5B and borrowings of ₩29.9B. Trailing free cash flow is ₩11.1B.

Valuation

At ₩30,100 the stock trades at a P/E of 9.5, P/B of 1.8, P/S of 0.5 and EV/EBITDA of 6.1. Its own year-end P/E ranged from 16.5 to 20.0 over 2021 to 2025, and year-end P/B from 2.1 to 4.8, so current multiples are below its history.

Peers are hard to compare. Hanwha has a P/E of 6.5 and KCC 0.9, while LG Chem, Hanwha Solutions and SKC show no P/E. Peer P/B values run from 0.3 to 2.1, against 1.8 for Dongnam Chemical. These peers are far larger.

The valuation model (5-year discounted cash flow, 6.9% rate, based on trailing figures to H1 2026) gives a base estimate of ₩42,398 per share, with a bear case of ₩16,811 and a bull case of ₩88,697. This is a model estimate based on the assumptions shown, not a target or a reason to buy or sell. The share price sits between the bear and base cases, and the wide range shows high sensitivity to assumptions.

Catalysts

• The half-year report filed on 2026-08-12 showed the trailing profit improvement, and the next filings will show whether it continues.
• Treasury stock acquisition results were reported on 2026-10-07, following a buyback decision on 2026-07-08.
• A cash dividend decision on 2026-07-08, amended on 2026-07-22, supports the 3.1% dividend yield.
• Filings on 2026-09-21 show a change in the largest shareholder's holdings and a 5%+ holding report, which may signal ownership changes.
• Investor flows over 20 days show institutions net buying ₩16.4M against net selling by foreign investors (₩24.2M) and retail investors (₩85.2M).

Risks

• Earnings have swung widely since 2021, with net income nearly halving by 2023, so the recent rise may not persist.
• The model's bear case of ₩16,811 is far below the current price, and the bull case is more than double the base estimate, so the estimate is highly uncertain.
• Borrowings of ₩29.9B against cash of ₩8.5B and liabilities to equity of 96.7% leave some balance sheet exposure.
• The company is small, with a ₩105.4B market cap and 0.2% foreign ownership, which can mean limited trading and larger price swings.
• No news headlines are available, and the data does not explain the margin change or the shareholder changes.

Closing view

The filed numbers show a clear recovery in profit, margins and returns, and the stock trades at lower multiples than in its own past years. Against that, revenue and earnings have been volatile, the model range is very wide, and the data does not explain what drove the improvement. The model's base estimate is above the current price, but it depends on assumptions that could change a great deal. Readers should weigh the earnings trend against the uncertainty and follow upcoming filings for confirmation.

Model estimate of fair value

Bear

₩16,811

-43%

Base

₩42,398

+43%

Bull

₩88,697

+199%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Base case of the 5-year discounted cash flow model on the stock's Valuation tab (statements TTM to H1 2026; discount rate 6.9%). Bear and Bull move the main assumptions by fixed steps. See and change the assumptions

Filings and data used

• Report on Treasury Stock Acquisition ResultsOct 7, 2026
• [Amendment] Disclosure of Corporate Governance ReportSep 22, 2026
• Change in largest shareholder's holdingsSep 21, 2026
• 5%+ holding reportSep 21, 2026
• Half-year report (Jun 2026)Aug 12, 2026
• Amended: Cash dividend decisionJul 22, 2026
• Cash dividend decisionJul 8, 2026
• Shareholder Register Closure for Cash/Stock Dividend (Record Date) DecisionJul 8, 2026
• Share buyback decisionJul 8, 2026
• Report on Treasury Stock Acquisition ResultsJul 7, 2026
• Change in largest shareholder's holdingsJun 11, 2026
• Disclosure of Corporate Governance ReportJun 1, 2026
• Daily prices up to 2026-10-22
• Financial statements, trailing 12 months as of H1 2026
• Our fair value model, statements as of TTM to H1 2026

Report history

1. Oct 23, 2026InitiationStart of coverage (reader request)Dongnam Chemical: Profit Recovery in H1 2026 Alongside Buybacks and a Wide Model Range